The LRRK2 G2019S transgenic mouse model expresses the most common pathogenic mutation in [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2), which causes autosomal dominant Parkinson's disease. This model enables study of kinase hyperactivation and testing of LRRK2-targeted therapeutics.
Genetic Background
Transgene Construction
| Component | Details | |-----------|---------| | Promoter | TetO (tetrahydropyridine-responsive) or ROSA26 | | Gene | Human LRRK2 with G2019S mutation | | Expression | Conditional (tetracycline-controlled) or constitutive | | Background | C57BL/6J |
The G2019S Mutation
The G2019S mutation is the most common pathogenic LRRK2 variant:
Location: Kinase domain, activation loop
Effect: Increases kinase activity 2-3 fold
Prevalence: ~5% familial PD, ~1% idiopathic PD
Penetrance: ~70% by age 80
Mechanism of Pathology
Kinase Hyperactivity
The G2019S mutation causes constitutive kinase activation:
Rab phosphorylation: Enhanced phosphorylation of Rab substrates (Rab8A, Rab10, Rab12)
Lysosomal dysfunction: Altered lysosomal trafficking and cathepsin activity
Mitochondrial dysfunction: Reduced complex I activity, increased ROS
Synaptic dysfunction: Altered dopamine release
Neuroinflammation: Microglial activation
Phenotypic Characteristics
Molecular Phenotype
...
The LRRK2 G2019S transgenic mouse model expresses the most common pathogenic mutation in [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2), which causes autosomal dominant Parkinson's disease. This model enables study of kinase hyperactivation and testing of LRRK2-targeted therapeutics.
Genetic Background
Transgene Construction
| Component | Details | |-----------|---------| | Promoter | TetO (tetrahydropyridine-responsive) or ROSA26 | | Gene | Human LRRK2 with G2019S mutation | | Expression | Conditional (tetracycline-controlled) or constitutive | | Background | C57BL/6J |
The G2019S Mutation
The G2019S mutation is the most common pathogenic LRRK2 variant:
Location: Kinase domain, activation loop
Effect: Increases kinase activity 2-3 fold
Prevalence: ~5% familial PD, ~1% idiopathic PD
Penetrance: ~70% by age 80
Mechanism of Pathology
Kinase Hyperactivity
The G2019S mutation causes constitutive kinase activation:
Rab phosphorylation: Enhanced phosphorylation of Rab substrates (Rab8A, Rab10, Rab12)
Lysosomal dysfunction: Altered lysosomal trafficking and cathepsin activity
[Gong et al., 2021 - LRRK2 knockin mice](https://doi.org/10.1038/s41586-021-03569-1)
[Steger et al., 2016 - LRRK2 kinase activity in vivo](https://doi.org/10.1038/ncomms12332)
[Daher et al., 2015 - AAV-LRRK2 G2019S model](https://doi.org/10.1016/j.nbd.2015.07.009)
[Cookson, 2010 - LRRK2 function and dysfunction](https://doi.org/10.1016/j.neuron.2010.03.020)
[Javed et al., 2019 - LRRK2 in Parkinson's disease](https://doi.org/10.1002/mds.27723)
Pathway Diagram
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving LRRK2 G2019S Transgenic Mouse Model discovered through SciDEX knowledge graph analysis: